| Comment : |
Levaquin - CRAVIT Description : The solution also contains the following ingredients: Sodium chloride, sodium hydroxide, hydrochloric acid (to make pH 4.8) and water for injection. Levofloxacin is (-)-(S)-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylic acid hemihydrate. It has a molecular formula of C18H20FN3O4·½H2O, molecular weight of 370.38 and a melting point of 222-230°C (decomposition). Levofloxacin is a light yellowish-white to yellowish-white crystals or crystalline powder, odorless and has a bitter taste. It is freely soluble in glacial acetic acid, sparingly soluble in water and methanol, slightly soluble in ethanol, and practically insoluble in ether. It is light sensitive. Cravit IV: The data demonstrate that from pH 0.6-5.8, the solubility of Cravit is essentially constant (approximately 100 mg/mL), Cravit is considered soluble to freely soluble in this pH range. Above pH 5.8, the solubility increase rapidly to its maximum at pH 6.7 ( 272 mg/mL) and is considered freely soluble in this range. Above pH 6.7, the solubility decrease and reach a maximum value (about 50 mg/mL) at a pH of approximately 6.9. Cravit has the potential to form stable coordinate compounds with many metal ions.
Levaquin - CRAVIT Indications : Treatment of adults (³16 years) with mild, moderate and severe infections caused by susceptible strains of the designated microorganisms in the following conditions: Pneumonia due to Staphylococcus aureus, Streptococcus pneumoniae (including penicillin-resistant strains), Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Moraxella catarrhalis, Chlamydia pneumoniae, Legionella pneumophila or Mycoplasma pneumoniae. Skin and skin structure infections (mild to moderate) including abscesses, cellulitis, furuncles, impetigo, pyoderma and wound infections due to Staphylococcus aureus, Streptococcus pyogenes, Enterococcus faecalis or Proteus mirabilis. Urinary tract infections (mild to moderate) due to Enterococcus faecalis, Enterobacter cloacae, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa or Staphylococcus saprophyticus. Pyelonephritis (mild to moderate) caused by Escherichia coli. Cravit: Acute sinusitis due to Streptococcus pneumoniae, Haemophilus influenzae or Moraxella catarrhalis. Acute exacerbation of chronic bronchitis due to Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae or Moraxella catarrhalis. Empirical treatment for community-acquired pneumonia most likely caused by organisms susceptible to levofloxacin.
Levaquin - CRAVIT Dosage : The serum creatinine should represent a steady state of renal function. Patients with Impaired Liver Function: No adjustment of dosage is required since levofloxacin is not metabolised to any relevant extent by liver and is mainly excreted by kidneys. Elderly: No adjustment is required in the elderly, other than that imposed by consideration of renal function. Cravit: Adults: 300-500 mg is usually administered orally 1-3 times a day. The dosage may be adjusted according to the kind of infection and symptoms. Empirical Treatment for Community-Acquired Pneumonia: 500 mg is administered once daily. As a general rule, the duration of treatment with Cravit should be limited to a minimum required for the treatment of diseases (10-14 days for sinusitis, 7 days for chronic bronchitis, 7-14 days for pneumonia, 7-10 days for skin and skin structure infection and 10 days for urinary tract infection and pyelonephritis) in order to avoid possible occurrence of resistant bacteria. Cravit IV: Administer by IV infusion. It is not for IM, intrathecal, intraperitoneal or SC administration. The dosage depends on the type and severity of the infection and the sensitivity of the presumed causative pathogen. The duration of therapy varies according to the course of the disease. As with any antibiotic therapy in general, administration of Cravit IV should be continued for a minimum of 48-72 hrs after the patient has become afebrile or evidence of bacterial eradication has been obtained. It is usually possible to switch from initial IV treatment to the oral route after a few days. Usual Dose: 500 mg administered by slow infusion over 60 min every 24 hrs as described Tables 1 and 2. (See Tables 1 and 2.) Compatibility: Cravit IV solution for infusion is compatible with the following solution for infusion: 0.9% Sodium Chloride Injection USP; 5% Dextrose Injection USP, 2.5% Dextrose in Ringer Solution. Combination solutions for parenteral nutrition (amino acids, carbohydrates, electrolytes). |
